These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25511188)

  • 21. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
    Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
    Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case of hypophysitis caused by nivolumab.
    Ishikawa M; Oashi K
    J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
    [No Abstract]   [Full Text] [Related]  

  • 24. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locally Advanced Unresectable Vaginal Melanoma: Response With Anti-Programmed Death Receptor 1.
    Chanal J; Kramkimel N; Guegan S; Moguelet P; Fourchotte V; Avril MF
    J Low Genit Tract Dis; 2016 Jan; 20(1):e4-5. PubMed ID: 26704337
    [No Abstract]   [Full Text] [Related]  

  • 27. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.
    Schneiderbauer R; Schneiderbauer M; Wick W; Enk AH; Haenssle HA; Hassel JC
    Acta Derm Venereol; 2017 Mar; 97(3):395-396. PubMed ID: 27868138
    [No Abstract]   [Full Text] [Related]  

  • 28. Biomarkers in melanoma.
    Griewank KG
    Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
    Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
    Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
    [No Abstract]   [Full Text] [Related]  

  • 30. BRAF inhibitor induced verrucal keratosis.
    Anforth R; Fernandez-Penas P
    Am J Dermatopathol; 2014 Feb; 36(2):192. PubMed ID: 23435364
    [No Abstract]   [Full Text] [Related]  

  • 31. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
    Michielin O; Hoeller C
    Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of metastatic malignant melanoma: on the way to individualized disease control.
    Vogt T
    Adv Exp Med Biol; 2014; 810():272-81. PubMed ID: 25207371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The brothers RAF.
    Kwong LN; Chin L
    Cell; 2010 Jan; 140(2):180-2. PubMed ID: 20141832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic melanoma treatment: Combining old and new therapies.
    Davey RJ; van der Westhuizen A; Bowden NA
    Crit Rev Oncol Hematol; 2016 Feb; 98():242-53. PubMed ID: 26616525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
    Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
    Long G
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
    [No Abstract]   [Full Text] [Related]  

  • 38. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Therapies for Melanoma: A New Standard of Care?
    Smalley KS; Eroglu Z; Sondak VK
    Am J Clin Dermatol; 2016 Apr; 17(2):99-105. PubMed ID: 26860106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selumetinib increases the efficacy of first-line dacarbazine.
    Cancer Discov; 2013 Jul; 3(7):OF16. PubMed ID: 23847359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.